G&L welcomes Pfizer announcement

G&L Scientific CEO Stephen Loughrey has welcomed the announcement by Pfizer that its coronavirus vaccine could be ready for use before the end of the year.

“Covid-19 is one of the greatest challenges facing us all. G&L welcomes these very positive steps by Pfizer and BioNTech in the ongoing fight to curb the pandemic, and we wish them every success as their work continues in this area.

“However, in the meantime, it remains essential that we all continue to play our part in observing the rules on social distancing, mask-wearing and sanitizing.”

Earlier this week Pfizer, and their German partner BioNTech SE, revealed initial trial results of their experimental vaccine were over 90 per cent effective. The companies are now seeking US emergency authorization for the drug and are hoping for a regulatory decision by December.

If granted, they estimate up to 50 million doses could be rolled out this year with a further 1.3 billion doses being produced in 2021.

The full statement can be found here

Back to news

G&L Scientific Holdings

Keep up to date with the latest industry news and trends
Newsletter Signup
Validation

Worldwide Locations

|
G&L Scientific G&L Scientific G&L Scientific G&L Scientific G&L Scientific